Aarhus University Seal / Aarhus Universitets segl

The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy. / Jakob, Thilo; Rauber, Michèle Myriam; Perez-Riverol, Amilcar; Spillner, Edzard; Blank, Simon.

I: Current Allergy and Asthma Reports, Bind 20, Nr. 9, 48, 2020.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Jakob, Thilo ; Rauber, Michèle Myriam ; Perez-Riverol, Amilcar ; Spillner, Edzard ; Blank, Simon. / The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy. I: Current Allergy and Asthma Reports. 2020 ; Bind 20, Nr. 9.

Bibtex

@article{a23794d1e8fd45009bc6b26cabed780e,
title = "The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy",
abstract = "Purpose of Review: In Hymenoptera venom allergy, the research focus has moved from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been described as a major allergen of honeybee venom (HBV) with potentially high relevance for diagnostics and therapy of venom allergy. Here, we review recent studies on Api m 10 characteristics as well as its role in component-resolved diagnostics and potential implications for venom-specific immunotherapy (VIT). Recent Findings: Api m 10 is a major allergen of low abundance in HBV. It is an obviously unstable protein of unknown function that exhibits homologs in other insect species. Despite its low abundance in HBV, 35 to 72% of HBV-allergic patients show relevant sensitization to this allergen. Api m 10 is a marker allergen for HBV sensitization, which in many cases can help to identify primary sensitization to HBV and, hence, to discriminate between genuine sensitization and cross-reactivity. Moreover, Api m 10 might support personalized risk stratification in VIT, as dominant sensitization to Api m 10 has been identified as risk factor for treatment failure. This might be of particular importance since Api m 10 is strongly underrepresented in some therapeutic preparations commonly used for VIT. Summary: Although the role of Api m 10 in HBV allergy and tolerance induction during VIT is not fully understood, it certainly is a useful tool to unravel primary sensitization and individual sensitization profiles in component-resolved diagnostics (CRD). Moreover, a potential of Api m 10 to contribute to personalized treatment strategies in HBV allergy is emerging.",
keywords = "Allergen-specific immunotherapy, Api m 10, Component-resolved allergy diagnostics, Honeybee venom allergy, Icarapin, Venom immunotherapy",
author = "Thilo Jakob and Rauber, {Mich{\`e}le Myriam} and Amilcar Perez-Riverol and Edzard Spillner and Simon Blank",
year = "2020",
doi = "10.1007/s11882-020-00943-3",
language = "English",
volume = "20",
journal = "Current Allergy & Asthma Reports",
issn = "1529-7322",
publisher = "Springer Healthcare",
number = "9",

}

RIS

TY - JOUR

T1 - The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy

AU - Jakob, Thilo

AU - Rauber, Michèle Myriam

AU - Perez-Riverol, Amilcar

AU - Spillner, Edzard

AU - Blank, Simon

PY - 2020

Y1 - 2020

N2 - Purpose of Review: In Hymenoptera venom allergy, the research focus has moved from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been described as a major allergen of honeybee venom (HBV) with potentially high relevance for diagnostics and therapy of venom allergy. Here, we review recent studies on Api m 10 characteristics as well as its role in component-resolved diagnostics and potential implications for venom-specific immunotherapy (VIT). Recent Findings: Api m 10 is a major allergen of low abundance in HBV. It is an obviously unstable protein of unknown function that exhibits homologs in other insect species. Despite its low abundance in HBV, 35 to 72% of HBV-allergic patients show relevant sensitization to this allergen. Api m 10 is a marker allergen for HBV sensitization, which in many cases can help to identify primary sensitization to HBV and, hence, to discriminate between genuine sensitization and cross-reactivity. Moreover, Api m 10 might support personalized risk stratification in VIT, as dominant sensitization to Api m 10 has been identified as risk factor for treatment failure. This might be of particular importance since Api m 10 is strongly underrepresented in some therapeutic preparations commonly used for VIT. Summary: Although the role of Api m 10 in HBV allergy and tolerance induction during VIT is not fully understood, it certainly is a useful tool to unravel primary sensitization and individual sensitization profiles in component-resolved diagnostics (CRD). Moreover, a potential of Api m 10 to contribute to personalized treatment strategies in HBV allergy is emerging.

AB - Purpose of Review: In Hymenoptera venom allergy, the research focus has moved from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been described as a major allergen of honeybee venom (HBV) with potentially high relevance for diagnostics and therapy of venom allergy. Here, we review recent studies on Api m 10 characteristics as well as its role in component-resolved diagnostics and potential implications for venom-specific immunotherapy (VIT). Recent Findings: Api m 10 is a major allergen of low abundance in HBV. It is an obviously unstable protein of unknown function that exhibits homologs in other insect species. Despite its low abundance in HBV, 35 to 72% of HBV-allergic patients show relevant sensitization to this allergen. Api m 10 is a marker allergen for HBV sensitization, which in many cases can help to identify primary sensitization to HBV and, hence, to discriminate between genuine sensitization and cross-reactivity. Moreover, Api m 10 might support personalized risk stratification in VIT, as dominant sensitization to Api m 10 has been identified as risk factor for treatment failure. This might be of particular importance since Api m 10 is strongly underrepresented in some therapeutic preparations commonly used for VIT. Summary: Although the role of Api m 10 in HBV allergy and tolerance induction during VIT is not fully understood, it certainly is a useful tool to unravel primary sensitization and individual sensitization profiles in component-resolved diagnostics (CRD). Moreover, a potential of Api m 10 to contribute to personalized treatment strategies in HBV allergy is emerging.

KW - Allergen-specific immunotherapy

KW - Api m 10

KW - Component-resolved allergy diagnostics

KW - Honeybee venom allergy

KW - Icarapin

KW - Venom immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85086511661&partnerID=8YFLogxK

U2 - 10.1007/s11882-020-00943-3

DO - 10.1007/s11882-020-00943-3

M3 - Review

C2 - 32548726

AN - SCOPUS:85086511661

VL - 20

JO - Current Allergy & Asthma Reports

JF - Current Allergy & Asthma Reports

SN - 1529-7322

IS - 9

M1 - 48

ER -